<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nexien Biopharma Inc — News on 6ix</title>
    <link>https://6ix.com/company/nexien-biopharma-inc</link>
    <description>Latest news and press releases for Nexien Biopharma Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 19 Feb 2021 14:03:21 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nexien-biopharma-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a4f178dffbe2df10ae14.webp</url>
      <title>Nexien Biopharma Inc</title>
      <link>https://6ix.com/company/nexien-biopharma-inc</link>
    </image>
    <item>
      <title>Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-inc-engages-core-ir-for-investor-relations-public-relations-and-shareholder-communications-services</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-inc-engages-core-ir-for-investor-relations-public-relations-and-shareholder-communications-services</guid>
      <pubDate>Fri, 19 Feb 2021 14:03:21 GMT</pubDate>
      <description>Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services.</description>
    </item>
    <item>
      <title>Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-inc-has-been-issued-a-us-patent-for-the-methods-and-compositions-for-treating-non-dystrophic-myotonia-and-myotonic-dystrophies-types-1-and-2</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-inc-has-been-issued-a-us-patent-for-the-methods-and-compositions-for-treating-non-dystrophic-myotonia-and-myotonic-dystrophies-types-1-and-2</guid>
      <pubDate>Thu, 16 Jul 2020 18:10:41 GMT</pubDate>
      <description>Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2.</description>
    </item>
    <item>
      <title>Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-announces-that-it-has-been-granted-a-patent-by-the-israeli-patent-office-covering-the-use-of-cannabinoids-and-terpenes-for-treatment-of-organophosphate-and-carbamate-toxicity-two-common-nerve-agents</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-announces-that-it-has-been-granted-a-patent-by-the-israeli-patent-office-covering-the-use-of-cannabinoids-and-terpenes-for-treatment-of-organophosphate-and-carbamate-toxicity-two-common-nerve-agents</guid>
      <pubDate>Thu, 18 Jul 2019 12:13:42 GMT</pubDate>
      <description>Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents.</description>
    </item>
    <item>
      <title>Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-to-present-at-the-microcap-conference-spring-investor-summit-on-tuesday-april-2nd</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-to-present-at-the-microcap-conference-spring-investor-summit-on-tuesday-april-2nd</guid>
      <pubDate>Thu, 28 Mar 2019 19:47:27 GMT</pubDate>
      <description>Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd.</description>
    </item>
    <item>
      <title>Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-announces-acceptance-of-patent-application-no-238946-by-israeli-patent-office</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-announces-acceptance-of-patent-application-no-238946-by-israeli-patent-office</guid>
      <pubDate>Tue, 05 Mar 2019 14:08:11 GMT</pubDate>
      <description>Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office.</description>
    </item>
    <item>
      <title>Nexien BioPharma to File Pre-IND Meeting Request with the FDA</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-to-file-pre-ind-meeting-request-with-the-fda</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-to-file-pre-ind-meeting-request-with-the-fda</guid>
      <pubDate>Tue, 26 Feb 2019 14:15:42 GMT</pubDate>
      <description>Nexien BioPharma to File Pre-IND Meeting Request with the FDA.</description>
    </item>
    <item>
      <title>Nexien BioPharma Announces Executive and Business Updates</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-announces-executive-and-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-announces-executive-and-business-updates</guid>
      <pubDate>Tue, 19 Feb 2019 14:09:11 GMT</pubDate>
      <description>Nexien BioPharma Announces Executive and Business Updates.</description>
    </item>
    <item>
      <title>Nexien BioPharma Releases Letter to Shareholders Announcing 2019 Plans, 2018 Activities, and Work to Come From Acquisitions</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-releases-letter-to-shareholders-announcing-2019-plans-2018-activities-and-work-to-come-from-acquisitions</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-releases-letter-to-shareholders-announcing-2019-plans-2018-activities-and-work-to-come-from-acquisitions</guid>
      <pubDate>Thu, 06 Dec 2018 14:02:44 GMT</pubDate>
      <description>Nexien BioPharma Releases Letter to Shareholders Announcing 2019 Plans, 2018 Activities, and Work to Come From Acquisitions.</description>
    </item>
    <item>
      <title>Nexien BioPharma And Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-and-ivy-league-university-medical-school-collaborate-on-pre-clinical-cannabinoid-studies</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-and-ivy-league-university-medical-school-collaborate-on-pre-clinical-cannabinoid-studies</guid>
      <pubDate>Wed, 28 Nov 2018 14:02:12 GMT</pubDate>
      <description>Nexien BioPharma And Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies.</description>
    </item>
    <item>
      <title>Uptick Newswire&apos;s Stock Day Podcast Interviews Nexien BioPharma CEO, Alex Wasyl, to Discuss the Acquisition of CRX Bio Holdings and The Company’s Future in The Pharmaceutical Space</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/uptick-newswires-stock-day-podcast-interviews-nexien-biopharma-ceo-alex-wasyl-to-discuss-the-acquisition-of-crx-bio-holdings-and-the-companys-future-in-the-pharmaceutical-space</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/uptick-newswires-stock-day-podcast-interviews-nexien-biopharma-ceo-alex-wasyl-to-discuss-the-acquisition-of-crx-bio-holdings-and-the-companys-future-in-the-pharmaceutical-space</guid>
      <pubDate>Mon, 26 Nov 2018 13:16:16 GMT</pubDate>
      <description>Uptick Newswire&apos;s Stock Day Podcast Interviews Nexien BioPharma CEO, Alex Wasyl, to Discuss the Acquisition of CRX Bio Holdings and The Company’s Future in The Pharmaceutical Space.</description>
    </item>
    <item>
      <title>Nexien BioPharma Advances in Clinical Use of a Cannabinoid-Based Formulation for the Treatment of Myotonic Dystrophies and Myotonia</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-advances-in-clinical-use-of-a-cannabinoid-based-formulation-for-the-treatment-of-myotonic-dystrophies-and-myotonia</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-advances-in-clinical-use-of-a-cannabinoid-based-formulation-for-the-treatment-of-myotonic-dystrophies-and-myotonia</guid>
      <pubDate>Tue, 06 Nov 2018 14:43:46 GMT</pubDate>
      <description>Nexien BioPharma Advances in Clinical Use of a Cannabinoid-Based Formulation for the Treatment of Myotonic Dystrophies and Myotonia.</description>
    </item>
    <item>
      <title>Nexien BioPharma Acquires Princeton-Based CRx Bio and Announces Additions to Senior Management</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-acquires-princeton-based-crx-bio-and-announces-additions-to-senior-management</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/nexien-biopharma-acquires-princeton-based-crx-bio-and-announces-additions-to-senior-management</guid>
      <pubDate>Tue, 30 Oct 2018 20:51:02 GMT</pubDate>
      <description>Nexien BioPharma Acquires Princeton-Based CRx Bio and Announces Additions to Senior Management.</description>
    </item>
    <item>
      <title>INTIVA BioPharma Inc. Announces Name Change to Nexien BioPharma Inc.</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-inc-announces-name-change-to-nexien-biopharma-inc</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-inc-announces-name-change-to-nexien-biopharma-inc</guid>
      <pubDate>Mon, 01 Oct 2018 18:30:54 GMT</pubDate>
      <description>INTIVA BioPharma Inc. Announces Name Change to Nexien BioPharma Inc..</description>
    </item>
    <item>
      <title>INTIVA BioPharma (OTCQB: NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE)</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-otcqb-ntva-files-a-listing-application-with-the-canadian-securities-exchange-cse</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-otcqb-ntva-files-a-listing-application-with-the-canadian-securities-exchange-cse</guid>
      <pubDate>Wed, 22 Aug 2018 20:26:10 GMT</pubDate>
      <description>INTIVA BioPharma (OTCQB: NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE).</description>
    </item>
    <item>
      <title>INTIVA BioPharma Inc (NTVA) Begins Trading on the OTCQB Venture Market</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-inc-ntva-begins-trading-on-the-otcqb-venture-market</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-inc-ntva-begins-trading-on-the-otcqb-venture-market</guid>
      <pubDate>Thu, 19 Jul 2018 12:11:09 GMT</pubDate>
      <description>INTIVA BioPharma Inc (NTVA) Begins Trading on the OTCQB Venture Market.</description>
    </item>
    <item>
      <title>OTC Markets Group Welcomes New OTCQB Companies – July 19</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/otc-markets-group-welcomes-new-otcqb-companies-july-19-1</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/otc-markets-group-welcomes-new-otcqb-companies-july-19-1</guid>
      <pubDate>Thu, 19 Jul 2018 11:00:00 GMT</pubDate>
      <description>OTC Markets Group Welcomes New OTCQB Companies – July 19.</description>
    </item>
    <item>
      <title>INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor</title>
      <link>https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-retains-dr-benedikt-schoser-as-an-advisor</link>
      <guid isPermaLink="true">https://6ix.com/company/nexien-biopharma-inc/news/intiva-biopharma-retains-dr-benedikt-schoser-as-an-advisor</guid>
      <pubDate>Thu, 12 Jul 2018 17:37:05 GMT</pubDate>
      <description>INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor.</description>
    </item>
  </channel>
</rss>